$CLRB Up 121% Premarket! 🚀 🔹 Cellectar Biosciences exploding as traders pile into its radiopharmaceutical oncology pipeline 🧬 🔹 Lead asset iopofosine I-131

$CLRB Up 121% Premarket! 🚀 🔹 Cellectar Biosciences exploding as traders pile into its radiopharmaceutical oncology pipeline 🧬 🔹 Lead asset iopofosine I-131 targets multiple cancers, including Waldenstrom’s macroglobulinemia, glioma & other hard-to-treat tumors 💊 🔹 Recent Phase 1b trial enrollm…